What is HC Wainwright’s Forecast for Nkarta Q1 Earnings?

Nkarta, Inc. (NASDAQ:NKTX) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Nkarta in a research note issued to investors on Thursday, March 27th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($0.49) per share for the quarter. HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Nkarta’s current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Nkarta’s Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.29) EPS, FY2026 earnings at ($1.46) EPS, FY2027 earnings at ($1.80) EPS and FY2028 earnings at ($1.54) EPS.

Several other research analysts have also recently weighed in on NKTX. Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Nkarta in a report on Thursday. Stifel Nicolaus cut their target price on Nkarta from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Nkarta presently has a consensus rating of “Buy” and a consensus price target of $14.86.

Nkarta Price Performance

NASDAQ NKTX opened at $2.00 on Monday. The company has a fifty day moving average price of $1.99 and a 200-day moving average price of $2.82. The firm has a market cap of $141.92 million, a price-to-earnings ratio of -1.06 and a beta of 0.90. Nkarta has a 1 year low of $1.31 and a 1 year high of $11.84.

Nkarta (NASDAQ:NKTX) last announced its quarterly earnings results on Wednesday, March 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.06.

Hedge Funds Weigh In On Nkarta

Several institutional investors and hedge funds have recently bought and sold shares of the company. Erste Asset Management GmbH bought a new stake in shares of Nkarta in the third quarter valued at $33,000. Invesco Ltd. purchased a new stake in Nkarta in the 4th quarter worth about $30,000. Sequoia Financial Advisors LLC bought a new stake in Nkarta in the 4th quarter valued at about $31,000. China Universal Asset Management Co. Ltd. purchased a new stake in Nkarta during the fourth quarter valued at about $37,000. Finally, Intech Investment Management LLC bought a new position in Nkarta during the third quarter worth about $74,000. 80.54% of the stock is owned by institutional investors.

Insider Buying and Selling at Nkarta

In other news, CEO Paul J. Hastings sold 17,378 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total transaction of $38,231.60. Following the completion of the sale, the chief executive officer now owns 319,859 shares in the company, valued at $703,689.80. This trade represents a 5.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 8.70% of the company’s stock.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.